Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Lilly Abemaciclib Research Grant Opportunity: Submit by Friday, July 10, 2020
Study Proposal Submission-NCCN iEnvision
NCCN Pfizer Axitinib Research Grant Opportunity: Submit by Wednesday, August 12, 2020
NCCN Pfizer Biosimilars Grant Opportunity - Submit by Wednesday, September 9, 2020
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

Find a clinical trial >


The University of California, San Francisco is an international leader in cancer research and patient care. The mission of the UCSF Helen Diller Family Comprehensive Cancer Center's clinical program is to provide comprehensive care through multidisciplinary collaboration and integrated services, to advance cancer therapies through clinical research, and to train future leaders in the treatment of patients with cancer. The collaborative approach to research and treatment is a hallmark of this program, enlisting the participation of surgeons, medical oncologists, radiation oncologists, pediatric oncologists, radiologists, and pathologists. Together with renowned UCSF investigators in fields ranging from molecular biology and biochemistry to epidemiology, biostatistics, and public policy analysis, UCSF clinical specialists are committed to translating scientific insights into lifesaving realities for cancer patients everywhere.

Highlights of the Center's comprehensive clinical program include:

· Translational research and innovative combined-modality trials for management of cancers of the prostate, breast, head and neck, colon, liver, lung, melanoma, and other solid tumors.

· Premier bone marrow transplantation.

· Highly advanced radiation therapy techniques including conformal radiotherapy, intraoperative radiotherapy, high-dose brachytherapy, intravascular brachytherapy, stereotactic radiotherapy, and radio-immunotherapy.

· World-renowned neuro-oncology program providing innovative therapy for brain and spinal cord cancers.

· Risk prevention/genetic screening.

· Specialized therapy for AIDS-related malignancies.

· Leaders in the treatment of pediatric malignancies.

UCSF's basic research on cancer follows in the tradition of J. Michael Bishop, MD, and Harold E. Varmus, MD, Nobel Prize recipients in 1989 for their work at UCSF on oncogenes. The Cancer Center received comprehensive designation from the National Cancer Institute in 1999, making it the only NCI-designated comprehensive cancer center from Seattle to Los Angeles. In November 2007 the Center was renamed the Helen Diller Family Comprehensive Cancer Center. Particular foci of multidisciplinary research have been recognized by an NCI Specialized Program of Research Excellence (SPORE) in breast cancer, first awarded in 1992; a SPORE in prostate cancer, awarded in 2000; and a SPORE in brain cancer, awarded in 2002. Also integral to the Center's programs are activities related to tobacco control, with projects ranging from laboratory science to public policy.

Current grant funding to UCSF investigators for cancer research projects from all sources totals more than $214 million annually.  In 2009, UCSF ranked 7th among all National Cancer Institute grantee institutions, with grants totaling $68.5 million.  Among the NCI-designated cancer centers nationwide, the UCSF Helen Diller Family Comprehensive Cancer Center ranks sixth in the size of its NCI Cancer Center Support Grant, and first among the 10 NCI-designated cancer centers located in California.